Discontinued — last reported Q4 '25
Over 3 years (FY 2021 to FY 2024), Acquisitions shows a downward trend with a -100.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $66.44M | $65.59M | -$515.00K | $751.00K | $0.00 | $0.00 | $16.12M | $815.00K | $2.03M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $8.02M |
| QoQ Change | — | — | — | -1.3% | -100.8% | +245.8% | -100.0% | — | — | -94.9% | +149.3% | -100.0% | — | — | — | — | — |
| YoY Change | — | — | — | — | — | — | -100.0% | -100.0% | >999% | +8.5% | — | — | -100.0% | -100.0% | -100.0% | — | — |